CN111298052A - Medicine for treating diabetes - Google Patents
Medicine for treating diabetes Download PDFInfo
- Publication number
- CN111298052A CN111298052A CN202010242112.3A CN202010242112A CN111298052A CN 111298052 A CN111298052 A CN 111298052A CN 202010242112 A CN202010242112 A CN 202010242112A CN 111298052 A CN111298052 A CN 111298052A
- Authority
- CN
- China
- Prior art keywords
- percent
- raw materials
- medicine
- root
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 55
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 229940079593 drug Drugs 0.000 title claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 42
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 32
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 32
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 32
- 239000002775 capsule Substances 0.000 claims abstract description 27
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 24
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 24
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 24
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 24
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 23
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 23
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 23
- 235000008434 ginseng Nutrition 0.000 claims abstract description 23
- 244000247747 Coptis groenlandica Species 0.000 claims abstract description 22
- 235000002991 Coptis groenlandica Nutrition 0.000 claims abstract description 22
- 240000000249 Morus alba Species 0.000 claims abstract description 19
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 19
- 241001061264 Astragalus Species 0.000 claims abstract description 18
- 235000006533 astragalus Nutrition 0.000 claims abstract description 18
- 210000004233 talus Anatomy 0.000 claims abstract description 18
- 241000756042 Polygonatum Species 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims description 49
- 238000003756 stirring Methods 0.000 claims description 28
- 239000000843 powder Substances 0.000 claims description 25
- 238000010298 pulverizing process Methods 0.000 claims description 23
- 241000208340 Araliaceae Species 0.000 claims description 22
- 238000001035 drying Methods 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 238000011049 filling Methods 0.000 claims description 13
- 241001633680 Polygonatum odoratum Species 0.000 claims description 12
- 238000007873 sieving Methods 0.000 claims description 12
- 238000002791 soaking Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 229920001661 Chitosan Polymers 0.000 claims description 6
- 229940107666 astragalus root Drugs 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 6
- 238000002137 ultrasound extraction Methods 0.000 claims description 6
- 244000241872 Lycium chinense Species 0.000 claims 1
- 235000015468 Lycium chinense Nutrition 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 49
- 210000004369 blood Anatomy 0.000 abstract description 41
- 239000008280 blood Substances 0.000 abstract description 41
- 102000004877 Insulin Human genes 0.000 abstract description 25
- 108090001061 Insulin Proteins 0.000 abstract description 25
- 229940125396 insulin Drugs 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 23
- 230000001603 reducing effect Effects 0.000 abstract description 14
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 9
- 102000003746 Insulin Receptor Human genes 0.000 abstract description 6
- 108010001127 Insulin Receptor Proteins 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 6
- 210000004153 islets of langerhan Anatomy 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 230000028327 secretion Effects 0.000 abstract description 4
- 230000033228 biological regulation Effects 0.000 abstract description 3
- 238000012258 culturing Methods 0.000 abstract description 3
- 230000007123 defense Effects 0.000 abstract description 3
- 210000000496 pancreas Anatomy 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000002110 toxicologic effect Effects 0.000 abstract description 3
- 231100000027 toxicology Toxicity 0.000 abstract description 3
- 239000011573 trace mineral Substances 0.000 abstract description 3
- 235000013619 trace mineral Nutrition 0.000 abstract description 3
- 210000002700 urine Anatomy 0.000 abstract description 3
- 230000009385 viral infection Effects 0.000 abstract description 3
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 230000006870 function Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 3
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical group OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 2
- 230000000225 effect on diabetes Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013557 nattō Nutrition 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- -1 selenium polysaccharide Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 102000014824 Crystallins Human genes 0.000 description 1
- 108010064003 Crystallins Proteins 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 102400000472 Sucrase Human genes 0.000 description 1
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229940086319 nattokinase Drugs 0.000 description 1
- 108010073682 nattokinase Proteins 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine for treating diabetes, which comprises the following raw materials in percentage by weight: 11.1 to 15.1 percent of ginseng fruit, 11.1 to 15.1 percent of polygonatum, 10.1 to 14.1 percent of kudzu root, 10.1 to 14.1 percent of medlar, 10.1 to 12.1 percent of mulberry leaf, 9.1 to 13.1 percent of malt, 8.5 to 12.5 percent of astragalus, 8.5 to 12.5 percent of rhizoma polygonati and 3.4 to 9.4 percent of coptis, and relates to the technical field of medicines. The medicine for treating diabetes mellitus can enhance the immunity and defense line of the organism, resist virus infection and protect the vitality of pancreas by combining the formula; the normal metabolism of islet cells is recovered, and the secretion function of islet B cells is improved; culturing damaged islet B cells to regenerate, strengthen insulin receptor and fully exert the regulation effect of insulin; replenishing trace elements closely related to diabetes mellitus energetically; rapidly reducing blood sugar and urine sugar, and actively preventing and treating complications; the health of the diabetes patient is comprehensively recovered; the Tangshu capsule is only suitable for type II diabetes, and toxicological experiments prove that the Tangshu capsule has no toxic or side effect, is safe, convenient and reliable, has small dosage, is easy to be accepted by patients and has quick and obvious curative effect.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a medicine for treating diabetes.
Background
Diabetes is a generally recognized persistent disease in the world at present, is caused by relative or absolute deficiency of insulin secretion in human bodies, and patients in China reach hundreds of millions of people in recent years. For a long time, Chinese and western medicine are dedicated to overcoming the persistent ailment and providing a plurality of medicines and methods, and the traditional Chinese medicine starts from treating the root cause, treats the symptoms and the symptoms in a dialectical way and deeply extracts related medicines, so that the blood sugar can be quickly and accurately reduced. Not only can control the blood sugar within an ideal range, but also can prevent and delay the occurrence and development of progressive blood vessel and nerve damage of diabetes.
The existing medicines for treating diabetes mellitus are mostly only capable of controlling blood sugar to a certain extent, treating symptoms and not treating the root causes, have poor treatment effect on diabetes mellitus, only play a role in health care in part of medicines for treating diabetes mellitus, and lack of ideal medicines capable of treating both symptoms and root causes quickly and effectively, so that the medicines for treating diabetes mellitus are provided.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides a medicine for treating diabetes, which solves the problems that the existing medicine for treating diabetes has poor treatment effect on diabetes, lacks ideal medicines which can be used for treating both symptoms and root causes and can be fast and effectively.
(II) technical scheme
In order to achieve the purpose, the invention is realized by the following technical scheme: a medicine for treating diabetes comprises the following raw materials in percentage by weight: 11.1 to 15.1 percent of ginseng fruit, 11.1 to 15.1 percent of polygonatum, 10.1 to 14.1 percent of kudzu root, 10.1 to 14.1 percent of medlar, 10.1 to 12.1 percent of mulberry leaf, 9.1 to 13.1 percent of malt, 8.5 to 12.5 percent of astragalus, 8.5 to 12.5 percent of rhizoma polygonati and 3.4 to 9.4 percent of coptis.
Preferably, the raw materials comprise the following components in percentage by weight: 11.1 percent of ginseng fruit, 11.1 percent of polygonatum, 10.1 percent of kudzuvine root, 10.1 percent of medlar, 10.1 percent of mulberry leaf, 13.1 percent of malt, 12.5 percent of astragalus, 12.5 percent of rhizoma polygonati and 9.4 percent of coptis.
Preferably, the raw materials comprise the following components in percentage by weight: 13.1 percent of ginseng fruit, 13.1 percent of polygonatum, 12.1 percent of kudzuvine root, 12.1 percent of medlar, 11.1 percent of mulberry leaf, 11.1 percent of malt, 10.5 percent of astragalus, 10.5 percent of rhizoma polygonati and 6.4 percent of coptis.
Preferably, the raw materials comprise the following components in percentage by weight: 15.1 percent of ginseng fruit, 15.1 percent of polygonatum, 14.1 percent of kudzuvine root, 14.1 percent of medlar, 12.1 percent of mulberry leaf, 9.1 percent of malt, 8.5 percent of astragalus, 8.5 percent of rhizoma polygonati and 3.4 percent of coptis.
Preferably, the preparation method of the medicine for treating diabetes comprises the following steps:
s1, ultrasonic extraction and crushing: pulverizing commercially available folium Mori with a pulverizing device, sieving with 40 mesh sieve, adding 40 times volume of water into folium Mori powder, soaking for 45min at 80 deg.C, extracting with ultrasonic wave for 10min, concentrating the filtrate, precipitating with ethanol, drying at 70 deg.C, pulverizing into 80-100 mesh folium Mori extract fine powder, and making into material A;
s2: extracting raw materials, namely soaking five raw materials of polygonatum odoratum, medlar, kudzu root, astragalus and sealwort in 10 times of water for 60min, decocting for three times, filtering the three decocted liquids, clarifying by using chitosan and a high-speed tube type centrifuge to obtain a clarified liquid, concentrating the clarified liquid into a paste, drying at 70 ℃, and crushing into 80-100 meshes of fine powder to prepare a material B;
s3: crushing raw materials: after drying, respectively pulverizing commercially available ginseng fruit, malt and coptis root, and sieving with 80-100 mesh fine powder to obtain material C;
s4: stirring raw materials: mixing the material A, the material B and the material C, stirring uniformly by using a stirring device, and filling into a sterilized bag for later use;
s5: preparing capsule granules: at this time, the mixture in S4 is processed by a capsule filling machine, and then filled into capsules 0.6 g each.
Preferably, when the commercially available mulberry leaves in S1 are pulverized by the pulverizing device, the rotation speed of the pulverizing device is controlled at 120r/min and 100-.
Preferably, in the step S2, five raw materials including polygonatum odoratum, medlar, kudzuvine root, astragalus root and rhizoma polygonati are decocted for 2 hours for the first time, 1 hour for the second time and 1 hour for the third time.
Preferably, when the materials A, B and C are mixed and stirred by the stirring device in the step S4, the rotating speed of the stirring device is controlled to be 80-100 r/min.
(III) advantageous effects
The invention provides a medicine for treating diabetes. Compared with the prior art, the method has the following beneficial effects: the medicine for treating diabetes comprises the following raw materials in percentage by weight: 11.1-15.1% of ginseng fruit, 11.1-15.1% of polygonatum odoratum, 10.1-14.1% of kudzu root, 10.1-14.1% of medlar, 10.1-12.1% of mulberry leaf, 9.1-13.1% of malt, 8.5-12.5% of astragalus root, 8.5-12.5% of rhizoma polygonati and 3.4-9.4% of coptis root, S1, ultrasonic extraction and crushing: pulverizing commercially available folium Mori with a pulverizing device, sieving with 40 mesh sieve, adding 40 times volume of water into folium Mori powder, soaking for 45min at 80 deg.C, extracting with ultrasonic wave for 10min, concentrating the filtrate, precipitating with ethanol, drying at 70 deg.C, pulverizing into 80-100 mesh folium Mori extract fine powder, and making into material A; s2: extracting raw materials, namely soaking five raw materials of polygonatum odoratum, medlar, kudzu root, astragalus and sealwort in 10 times of water for 60min, decocting for three times, filtering the three decocted liquids, clarifying by using chitosan and a high-speed tube type centrifuge to obtain a clarified liquid, concentrating the clarified liquid into a paste, drying at 70 ℃, and crushing into 80-100 meshes of fine powder to prepare a material B; s3: crushing raw materials: after drying, respectively pulverizing commercially available ginseng fruit, malt and coptis root, and sieving with 80-100 mesh fine powder to obtain material C; s4: stirring raw materials: mixing the material A, the material B and the material C, stirring uniformly by using a stirring device, and filling into a sterilized bag for later use; s5: preparing capsule granules: processing the mixture in the S4 by a capsule filling machine, and then filling the mixture into No. 0 capsules, wherein each capsule is 0.6 g, and the composition of the formula can enhance the immunity and defense line of the organism, resist virus infection and protect the activity of pancreas; the normal metabolism of islet cells is recovered, and the secretion function of islet B cells is improved; culturing damaged islet B cells to regenerate, strengthen insulin receptor and fully exert the regulation effect of insulin; replenishing trace elements closely related to diabetes mellitus energetically; rapidly reducing blood sugar and urine sugar, and actively preventing and treating complications; the health of the diabetes patient is comprehensively recovered; the Tangshu capsule is only suitable for type II diabetes, toxicological experiments prove that the Tangshu capsule has no toxic or side effect, safety, convenience and reliability, small dosage, easy acceptance by patients and quick and obvious curative effect, and the total effective rate of 95 patients is 93.68 percent when the Tangshu capsule is applied and treated, wherein 56 patients with obvious effect account for 59 percent.
The kudzu root extract has the function of reducing blood sugar: the kudzu root has obvious blood sugar reducing effect on alloxan hyperglycemia, can improve sugar tolerance and also has blood sugar reducing effect on adrenergic hyperglycemia; the concentrated radix Puerariae extract can enter human body in the state of plant molecule, repair and protect islet cells, inhibit glucagon secretion, and promote insulin secretion, thereby reducing blood sugar. Meanwhile, the kudzu root extract can also improve an insulin resistance system, enhance the sensitivity of an insulin receptor, promote the binding affinity with the insulin receptor and improve the biological effect of insulin cells, thereby realizing stable and rapid blood glucose reduction; the kudzu root extract can effectively block the complicating diseases: the kudzu root extract can activate blood vessels of diabetics in a short time, soften blood vessel walls and increase the elasticity of smooth muscles, so that the vascular resistance is reduced, the blood flow speed is increased, the deposition of substances in the blood vessels is reduced, the blood circulation in a human body is improved, and the incidence rate of blood sugar, blood fat and cardiovascular and cerebrovascular diseases is reduced; nephropathy is one of the typical complications of diabetes, and is the main cause of death and disability of diabetics. The high-quality radix puerariae extract of our company has a good inhibition effect on non-enzymatic glycosylation of protein, and can also reduce pericyte damage caused by non-enzymatic glycosylation of protein, the radix puerariae alcohol extract has an obvious inhibition effect on non-enzymatic glycosylation of Human Serum Albumin (HSA), and the inhibition rate is 40%; has obvious inhibiting effect on non-enzymatic glycosylation of lens protein, and the inhibiting rate is 46 percent. Is the best choice for protecting and strengthening the kidney function and is the most direct reason for obviously improving the diabetic retinopathy; the antioxidation of the kudzu root extract: the highly concentrated active component of radix Puerariae extract can effectively scavenge free radicals, inhibit oxidation of pancreatic islet, and effectively scavenge free radicals in human body from different directions in cooperation with selenium polysaccharide. Thereby inhibiting the oxidative damage of tissues such as erythrocyte membranes, liver, spleen, brain and the like, and effectively preventing and controlling diabetes and complications thereof. Besides, it can also raise immunity and memory of human body.
The ginseng fruit saponin and the polygonatum saponin in the medicine have stronger immune function, and particularly have more remarkable effects on humoral immunity and cellular immunity; modern pharmacological research shows that both kudzuvine root and malt have the function of reducing blood sugar.
The traditional Chinese medicines in the formula have strong hypoglycemic effect on hyperglycemia caused by glucose, epinephrine, alloxan, streptozotocin, pancreatic hyperglycemia and the like; besides, the traditional Chinese medicine composition has better prevention and treatment effects on complications such as hypertension, hyperlipidemia, heart disease, cerebral obstruction, stomach and kidney, retinopathy and the like caused by diabetes.
Malt: the malt is rich in nutrition and is a natural substance for reducing blood sugar, and the malt can reduce the blood sugar of rabbits and people by 40% or more by oral administration, and the action can last for 7 hours; the malt contains rich maltose, and is a few nutrient substance which can reduce blood sugar and supplement sugar required by human body. The malt is the preferred health food for the middle-aged and the elderly, especially for women, because the malt belongs to high dietary fiber food, after entering the intestinal tract, the malt can help the intestinal peristalsis, accelerate the nutrient absorption and food emptying in the intestinal tract, take away the fat remained in the intestinal tract, and is beneficial to the metabolism of the human body, so the malt has the reputation of 'intestinal tract scavenger'; both Kudzuvine root and malt have the function of reducing blood sugar. Pure extracts of radix Puerariae, fructus Hordei Germinatus, and fructus Hordei Germinatus extract (selenium-rich powder) have effects of resisting insulin resistance, promoting B cell repair, and enhancing insulin activity. And can reduce blood sugar, improve insulin sensitivity and improve insulin resistance to different degrees.
Berberine has effects of promoting regeneration of injured islet B cells and insulin secretion of residual B cells until islet function is completely recovered, inhibiting hepatic gluconeogenesis, promoting glycolysis of peripheral tissues to glucose, and resisting glycemic hormone.
Medlar and the like contain rich microelements which are closely related to diabetes, particularly chromium elements play an important role in increasing the number and affinity of insulin receptors and reducing blood sugar.
The important components of the mulberry leaves are alkaloid compounds, wherein the most important is deoxynojirimycin, and modern medicine proves that DNJ can inhibit the decomposition of sucrase, maltase, α -glucosaccharase and α -amylase on starch and sugar in a human body after entering the human body, thereby blocking the absorption of the human body on the sugar and inhibiting the rise of blood sugar to achieve the effect of preventing and treating diabetes mellitus, and the 'source sugar control and negative insulin reduction' are the treatment directions of diabetes mellitus accepted by the medical community at present, namely the speed and the quantity of food converted into blood sugar are controlled, the blood sugar is prevented from rising, and the method belongs to the prior control, so that the deoxynojirimycin has the effect of reducing the blood sugar without increasing insulin.
Drawings
FIG. 1 is a flow chart of the manufacturing process of the present invention;
FIG. 2 is a chart comparing the present invention with the market-oriented medicine for treating diabetes;
FIG. 3 is a chart comparing the drugs for diabetes treatment according to the embodiment of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Referring to fig. 1-3, an embodiment of the present invention provides a technical solution: the medicine for treating diabetes comprises the following specific embodiments:
example 1
The raw materials comprise the following components in percentage by weight: 11.1 percent of ginseng fruit, 11.1 percent of polygonatum, 10.1 percent of kudzuvine root, 10.1 percent of medlar, 10.1 percent of mulberry leaf, 13.1 percent of malt, 12.5 percent of astragalus, 12.5 percent of rhizoma polygonati and 9.4 percent of coptis.
In the invention, the preparation method of the medicine for treating diabetes comprises the following steps:
s1, ultrasonic extraction and crushing: pulverizing commercially available folium Mori with a pulverizing device, sieving with 40 mesh sieve, adding 40 times volume of water into folium Mori powder, soaking for 45min at 80 deg.C, extracting with ultrasonic wave for 10min, concentrating the filtrate, precipitating with ethanol, drying at 70 deg.C, and pulverizing into 80 mesh folium Mori extract fine powder to obtain material A;
s2: extracting raw materials, namely soaking five raw materials of polygonatum odoratum, medlar, kudzu root, astragalus and sealwort in 10 times of water for 60min, decocting for three times, filtering the three decocted liquids, clarifying by using chitosan and a high-speed tube type centrifuge to obtain a clarified liquid, concentrating the clarified liquid into a paste, drying at 70 ℃, and crushing into 80-mesh fine powder to prepare a material B;
s3: crushing raw materials: after drying, respectively crushing commercially available ginseng fruit, malt and coptis root, and sieving the crushed ginseng fruit, malt and coptis root into 80-mesh fine powder to prepare a material C;
s4: stirring raw materials: mixing the material A, the material B and the material C, stirring uniformly by using a stirring device, and filling into a sterilized bag for later use;
s5: preparing capsule granules: at this time, the mixture in S4 is processed by a capsule filling machine, and then filled into capsules 0.6 g each.
In the present invention, when the commercially available mulberry leaves at S1 are pulverized by the pulverizer, the rotation speed of the pulverizer is controlled to 100 r/min.
In the invention, in S2, five raw materials including polygonatum odoratum, medlar, kudzu vine root, astragalus root and sealwort are decocted for 2 hours for the first time, 1 hour for the second time and 1 hour for the third time.
In the invention, when the material A, the material B and the material C are mixed and stirred by the stirring device in the step S4, the rotating speed of the stirring device is controlled to be 80 r/min.
Example 2
The raw materials comprise the following components in percentage by weight: 13.1 percent of ginseng fruit, 13.1 percent of polygonatum, 12.1 percent of kudzuvine root, 12.1 percent of medlar, 11.1 percent of mulberry leaf, 11.1 percent of malt, 10.5 percent of astragalus, 10.5 percent of rhizoma polygonati and 6.4 percent of coptis.
In the invention, the preparation method of the medicine for treating diabetes comprises the following steps:
s1, ultrasonic extraction and crushing: pulverizing commercially available folium Mori with a pulverizing device, sieving with 40 mesh sieve, adding 40 times volume of water into folium Mori powder, soaking for 45min at 80 deg.C, extracting with ultrasonic wave for 10min, concentrating the filtrate, precipitating with ethanol, drying at 70 deg.C, and pulverizing into 90 mesh folium Mori extract fine powder to obtain material A;
s2: extracting raw materials, namely soaking five raw materials of polygonatum odoratum, medlar, kudzu root, astragalus and sealwort in 10 times of water for 60min, decocting for three times, filtering the three decocted liquids, clarifying by using chitosan and a high-speed tube type centrifuge to obtain a clarified liquid, concentrating the clarified liquid into a paste, drying at 70 ℃, and crushing into 90-mesh fine powder to prepare a material B;
s3: crushing raw materials: after drying, respectively crushing commercially available ginseng fruit, malt and coptis root, and sieving the crushed ginseng fruit, malt and coptis root into 90-mesh fine powder to prepare a material C;
s4: stirring raw materials: mixing the material A, the material B and the material C, stirring uniformly by using a stirring device, and filling into a sterilized bag for later use;
s5: preparing capsule granules: at this time, the mixture in S4 is processed by a capsule filling machine, and then filled into capsules 0.6 g each.
In the present invention, when the commercially available mulberry leaves at S1 are pulverized by the pulverizer, the rotation speed of the pulverizer is controlled to 110 r/min.
In the invention, in S2, five raw materials including polygonatum odoratum, medlar, kudzu vine root, astragalus root and sealwort are decocted for 2 hours for the first time, 1 hour for the second time and 1 hour for the third time.
In the invention, when the material A, the material B and the material C are mixed and stirred by the stirring device in the step S4, the rotating speed of the stirring device is controlled at 90 r/min.
Example 3
The raw materials comprise the following components in percentage by weight: 15.1 percent of ginseng fruit, 15.1 percent of polygonatum, 14.1 percent of kudzuvine root, 14.1 percent of medlar, 12.1 percent of mulberry leaf, 9.1 percent of malt, 8.5 percent of astragalus, 8.5 percent of rhizoma polygonati and 3.4 percent of coptis.
In the invention, the preparation method of the medicine for treating diabetes comprises the following steps:
s1, ultrasonic extraction and crushing: pulverizing commercially available folium Mori with a pulverizing device, sieving with 40 mesh sieve, adding 40 times volume of water into folium Mori powder, soaking for 45min at 80 deg.C, extracting with ultrasonic wave for 10min, concentrating the filtrate, precipitating with ethanol, drying at 70 deg.C, and pulverizing into 100 mesh folium Mori extract fine powder to obtain material A;
s2: extracting raw materials, namely soaking five raw materials of polygonatum odoratum, medlar, kudzu root, astragalus and sealwort in 10 times of water for 60min, decocting for three times, filtering the three decocted liquids, clarifying by using chitosan and a high-speed tube type centrifuge to obtain a clarified liquid, concentrating the clarified liquid into a paste, drying at 70 ℃, and crushing into 100-mesh fine powder to prepare a material B;
s3: crushing raw materials: after drying, respectively crushing commercially available ginseng fruit, malt and coptis root, and sieving the crushed ginseng fruit, malt and coptis root fine powder by 100 meshes to prepare a material C;
s4: stirring raw materials: mixing the material A, the material B and the material C, stirring uniformly by using a stirring device, and filling into a sterilized bag for later use;
s5: preparing capsule granules: at this time, the mixture in S4 is processed by a capsule filling machine, and then filled into capsules 0.6 g each.
In the present invention, when the commercially available mulberry leaves at S1 are pulverized by the pulverizer, the rotation speed of the pulverizer is controlled to 120 r/min.
In the invention, in S2, five raw materials including polygonatum odoratum, medlar, kudzu vine root, astragalus root and sealwort are decocted for 2 hours for the first time, 1 hour for the second time and 1 hour for the third time.
In the present invention, when the material A, the material B and the material C are mixed and stirred by the stirring device in the step S4, the rotation speed of the stirring device is controlled at 100 r/min.
Clinical experiments
Example 1 Shen De Zhi: male 71 year old famous painter, patient self-documented: the doctor lets take insulin for more than ten years, the insulin is taken for 3 times every day, 20 units are taken in the morning, 15 units are taken in the noon and 15 units are taken in the evening, and the blood sugar before meals can be controlled to be about 8.5 mmol/L. The people have suffered from cerebral embolism, cataract and serious eye strain, which greatly influences our career.
Tangshu tablets were taken three times a day, two tablets each time, at 1 month of 2012, with constant insulin dosage. After the Tangshu tablets are taken for one month, the blood sugar before meals is reduced to 6mmol/L, the whole body becomes vigorous, and eyes are bright; at the moment, I begin to reduce the dosage of insulin, beat 3 times a day with 15 units in the morning, 10 units in the noon and 15 units in the evening; then, the dosage of insulin is gradually reduced according to the condition of blood sugar, the insulin is completely stopped within four months, only the Tangshu tablet is taken, the blood sugar control is very stable, the body is vigorous, eyes are good, and fine lines are also clearly seen when the Tangshu tablet is drawn. Tangshu tablet not only cures our diabetes, but also cures many syndromes, and happy I uses a painting brush to express the mood for expelling the disease magic, and draws at the moment just like flowing of elegant air, and the pen is quiet and red, and the pen is led to the spirit.
Example 2: zhang Yuling: female 70 year old famous painter, patient self-written: after the patient suffers from the diabetes for more than 20 years, the highest fasting blood sugar reaches 20.5mmol/L, western medicines are taken at the beginning, and the blood sugar can not be adjusted later, so that the doctor can take insulin for ten years, the insulin is taken for 3 times every day, 15 units are taken in the morning, 10 electric potentials are taken at noon and 10 electric potentials are taken at night, and the blood sugar before meals can be controlled to be about 8.5 mmol/L. The eyes are spent as early as possible, the painter strokes the eyes, and the painter stops the strokes, so that the diabetes syndrome has great influence on the career.
The Tangshu tablet is taken in one month in 2012, two tablets are taken 3 times a day, and the dosage of the insulin is unchanged. After the Tangshu tablet is taken for one month, the blood sugar before meals is reduced to 6.5mmol/L, the whole body becomes vigorous, and the eyes are bright. At the moment, I start to reduce the insulin dosage to 10 units in the morning, 10 units in the noon and 10 units in the evening, then gradually reduce the insulin dosage according to the blood sugar condition, stop all insulin in four months, only take the Tangshu tablet, the Tangshu tablet is also gradually reduced according to the blood sugar condition, and stop the Tangshu tablet in three months.
At present, I insist on walking for at least one hour every night, eat light food mostly, eat low GI food mostly, and keep blood sugar diseases in a normal range.
Example 3: liu Jian Wei, famous director, five and sixteen years of age this year. Because of working fatigue for many years, diet irregularity often shows more than three and less symptoms, daily emaciation and some dizziness, the doctor visits the hospital for examination in 2019 and 1 month, the blood sugar before meal is 20mmol/L, the glycosylated hemoglobin is 11 percent, and the diabetes is diagnosed. Hospitalization with 40 units of insulin per day, as well as oral delivery of both damekang and baizaipin; after ten days, the blood sugar is reduced to 8.5mmol/L, the glycosylated hemoglobin is 10 percent, and insulin is continuously pumped and the Dameikang and the Baoxepin are taken after discharge. After three months, the inventor finds that the Tangshu tablets are taken three times a day, natto kinase is also taken for the fatty liver, western medicines are completely stopped, and insulin is stopped. After one week, reducing blood sugar to 5.5mmol/L, continuing to use Tangshu tablet and natto, and reducing insulin dosage by one third; one month later, insulin is reduced by one third, three months later, insulin is completely stopped, only two tablets of Tangshu tablets and natto are taken three times a day, blood sugar is kept about 5.5%, and glycosylated hemoglobin is reduced to below 8%. At present, the complexion is ruddy, the sleep is peaceful, the walking becomes forceful, and the director also becomes vigorous.
Comparative experiment
A certain diabetes treatment drug manufacturer respectively selects diabetes treatment drugs in consistent and consistent in the formula preparation process of the embodiments S1-S3 and diabetes treatment drugs in the market to carry out drug effect comparison experiments, as can be seen from figure 2, the diabetes treatment drugs in consistent and consistent in the formula preparation process of the embodiments S1-S3 have blood sugar of 5.7mmol/L after use and the diabetes treatment drugs in the market and the blood sugar of 8.5mmol/L after use, so that the drug efficiency of the diabetes treatment drugs prepared by the invention is far superior to that of the diabetes treatment drugs in consistent and consistent in the market, as can be seen from figure 3, the drug efficiency of the diabetes treatment drugs prepared by the embodiment 2 is the best, and is the optimal scheme; the other two are acceptable.
In conclusion, the combination of the formula can enhance the immunity and defense line of the organism, resist virus infection and protect the activity of pancreas; the normal metabolism of islet cells is recovered, and the secretion function of islet B cells is improved; culturing damaged islet B cells to regenerate, strengthen insulin receptor and fully exert the regulation effect of insulin; replenishing trace elements closely related to diabetes mellitus energetically; rapidly reducing blood sugar and urine sugar, and actively preventing and treating complications; the health of the diabetes patient is comprehensively recovered; the Tangshu capsule is only suitable for type II diabetes, toxicological experiments prove that the Tangshu capsule has no toxic or side effect, safety, convenience and reliability, small dosage, easy acceptance by patients and quick and obvious curative effect, and the total effective rate of 95 patients is 93.68 percent when the Tangshu capsule is applied and treated, wherein 56 patients with obvious effect account for 59 percent.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (8)
1. A medicine for treating diabetes is characterized in that: the raw materials comprise the following components in percentage by weight: 11.1 to 15.1 percent of ginseng fruit, 11.1 to 15.1 percent of polygonatum, 10.1 to 14.1 percent of kudzu root, 10.1 to 14.1 percent of medlar, 10.1 to 12.1 percent of mulberry leaf, 9.1 to 13.1 percent of malt, 8.5 to 12.5 percent of astragalus, 8.5 to 12.5 percent of rhizoma polygonati and 3.4 to 9.4 percent of coptis.
2. A diabetes treatment drug according to claim 1, characterized in that: the raw materials comprise the following components in percentage by weight: 11.1 percent of ginseng fruit, 11.1 percent of polygonatum, 10.1 percent of kudzuvine root, 10.1 percent of medlar, 10.1 percent of mulberry leaf, 13.1 percent of malt, 12.5 percent of astragalus, 12.5 percent of rhizoma polygonati and 9.4 percent of coptis.
3. A diabetes treatment drug according to claim 1, characterized in that: the raw materials comprise the following components in percentage by weight: 13.1 percent of ginseng fruit, 13.1 percent of polygonatum, 12.1 percent of kudzuvine root, 12.1 percent of medlar, 11.1 percent of mulberry leaf, 11.1 percent of malt, 10.5 percent of astragalus, 10.5 percent of rhizoma polygonati and 6.4 percent of coptis.
4. A diabetes treatment drug according to claim 1, characterized in that: the raw materials comprise the following components in percentage by weight: 15.1 percent of ginseng fruit, 15.1 percent of polygonatum, 14.1 percent of kudzuvine root, 14.1 percent of medlar, 12.1 percent of mulberry leaf, 9.1 percent of malt, 8.5 percent of astragalus, 8.5 percent of rhizoma polygonati and 3.4 percent of coptis.
5. A diabetes treatment drug according to any one of claims 1 to 4, characterized in that: the preparation method specifically comprises the following steps:
s1, ultrasonic extraction and crushing: pulverizing commercially available folium Mori with a pulverizing device, sieving with 40 mesh sieve, adding 40 times volume of water into folium Mori powder, soaking for 45min at 80 deg.C, extracting with ultrasonic wave for 10min, concentrating the filtrate, precipitating with ethanol, drying at 70 deg.C, pulverizing into 80-100 mesh folium Mori extract fine powder, and making into material A;
s2: extracting raw materials, namely soaking five raw materials of polygonatum odoratum, medlar, kudzu root, astragalus and sealwort in 10 times of water for 60min, decocting for three times, filtering the three decocted liquids, clarifying by using chitosan and a high-speed tube type centrifuge to obtain a clarified liquid, concentrating the clarified liquid into a paste, drying at 70 ℃, and crushing into 80-100 meshes of fine powder to prepare a material B;
s3: crushing raw materials: after drying, respectively pulverizing commercially available ginseng fruit, malt and coptis root, and sieving with 80-100 mesh fine powder to obtain material C;
s4: stirring raw materials: mixing the material A, the material B and the material C, stirring uniformly by using a stirring device, and filling into a sterilized bag for later use;
s5: preparing capsule granules: at this time, the mixture in S4 is processed by a capsule filling machine, and then filled into capsules 0.6 g each.
6. The method for preparing a medicine for treating diabetes according to claim 5, wherein the medicine comprises: when the commercially available mulberry leaves in the S1 are crushed by the crushing device, the rotating speed of the crushing device is controlled at 120r/min and 100-.
7. The method for preparing a medicine for treating diabetes according to claim 5, wherein the medicine comprises: in the step S2, five raw materials including polygonatum odoratum, Chinese wolfberry, kudzu vine root, astragalus root and sealwort are decocted for 2 hours for the first time, 1 hour for the second time and 1 hour for the third time.
8. The method for preparing a medicine for treating diabetes according to claim 5, wherein the medicine comprises: and in the step S4, when the material A, the material B and the material C are mixed and stirred by the stirring device, the rotating speed of the stirring device is controlled to be 80-100 r/min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010242112.3A CN111298052A (en) | 2020-03-31 | 2020-03-31 | Medicine for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010242112.3A CN111298052A (en) | 2020-03-31 | 2020-03-31 | Medicine for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111298052A true CN111298052A (en) | 2020-06-19 |
Family
ID=71151668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010242112.3A Withdrawn CN111298052A (en) | 2020-03-31 | 2020-03-31 | Medicine for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111298052A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111643641A (en) * | 2020-07-08 | 2020-09-11 | 上海中医药大学 | Food therapy formula for clearing heat, invigorating spleen and tonifying kidney and preparation method and application thereof |
-
2020
- 2020-03-31 CN CN202010242112.3A patent/CN111298052A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111643641A (en) * | 2020-07-08 | 2020-09-11 | 上海中医药大学 | Food therapy formula for clearing heat, invigorating spleen and tonifying kidney and preparation method and application thereof |
| CN111643641B (en) * | 2020-07-08 | 2022-02-11 | 上海中医药大学 | Food therapy formula for clearing heat, invigorating spleen and tonifying kidney and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN102526479A (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN102551065A (en) | Blood sugar reducing food series | |
| CN105030984B (en) | A kind of semen litchi health care oral liquid and preparation method with hypoglycemic, tune rouge and alleviation diabetic complication | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN114177247A (en) | Anticancer blood sugar-controlling inonotus obliquus pure powder tablet and preparation method and application thereof | |
| CN1939506B (en) | Preparation with blood-pressure, blood-sugar and blood-fat lowering functions and its making method | |
| CN104815166B (en) | A kind of Chinese medicine composition for treating diabetes and its preparation and application | |
| CN111298052A (en) | Medicine for treating diabetes | |
| CN1324627A (en) | Diabetes treating medicine and its prepn. method | |
| CN108403818A (en) | A kind of composition of auxiliary hyperglycemic and application thereof | |
| CN102872334B (en) | Application of medicinal composition for treating diabetes mellitus | |
| CN101129638A (en) | Health care medicinal liquor | |
| CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN100500174C (en) | Medicine composition used for lowering blood-sugar, preparation method and use thereof | |
| CN115120684A (en) | Traditional Chinese medicine formula for treating diabetes and processing method thereof | |
| CN102198174B (en) | Traditional Chinese medicine formulated preparation for nourishing kidney, removing heat from liver, reducing sugar and regulating fat, and preparation method thereof | |
| CN106722918A (en) | A kind of hypoglycemia healthcare food and preparation method thereof | |
| CN103989168A (en) | Composition capable of lowering sugar and fat | |
| CN104940594A (en) | Application of brain preparation in the preparation of medicine for curing II-type diabetes mellitus and complications thereof | |
| CN104474103A (en) | Natural plant hypoglycemic agent and preparation method thereof | |
| CN104352748A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN104922445B (en) | A kind of Traditional Chinese medicine compound composition and the preparation method and application thereof with treatment heart failure effect | |
| CN108967787A (en) | A kind of India's ivy gourd leaf beverage and preparation method thereof with effect of lowering blood sugar | |
| CN103191222A (en) | Application of hedan preparation in preparation of diabetes medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200619 |
|
| WW01 | Invention patent application withdrawn after publication |